Technology / WORLD

BNDES approves R$298 million for Althaia drug research and development

BNDES approved R$298 million in two operations for Althaia’s R&D center, radical innovation work and a 31-medicine development portfolio.

Reading sizeSources ↓Share story ↗
Conceptual illustration of technology, processors and connected information.Illustration
Symbolic illustration

Brazil’s development bank BNDES said on October 24 that it had approved two financings totaling R$298 million for Althaia, a pharmaceutical company based in Atibaia, São Paulo state. Both approvals use the BNDES Mais Inovação program. The bank described the support as funding for research, development and innovation; approval does not mean all funds have been disbursed or medicines have reached patients.

The first operation is R$100 million for the company’s research and development center and medicines BNDES describes as radical innovations. The release names unmet-need areas including obesity, metabolic disorders and neurodegeneration. It also cites a probiotic formulation for gastrointestinal infections, a formulation for digestive disorders and use of artificial intelligence to discover and develop bioactive peptides aimed at sarcopenia. These are research directions, not demonstrated clinical effects or approved indications.

BNDES says the project includes new equipment for the Epicenter R&D center and expects more than 35 new research and development jobs. The release also refers to a partnership with EMBRAPII, the Brazilian Company for Industrial Research and Innovation, and other research institutions. It does not provide a hiring schedule or allocate the first financing among individual research lines, so the R$100 million is an approved project amount, not a budget for one medicine.

A second approval, for R$198 million, is intended to support development of 31 human medicines. BNDES says 20 are generic products entering the Brazilian market for the first time and 11 are incremental innovations. Work may include pharmaceutical technology, analytical validation, stability studies, pilot batches, pharmaceutical equivalence and bioequivalence, and clinical trials where applicable. The source gives no launch date for each product and does not say development or regulatory approval is complete.

The two operations therefore cover distinct parts of Althaia’s pipeline: R&D infrastructure and radical innovation on one side, and a named 31-product development portfolio on the other. The 31 medicines should not be described as 31 novel active ingredients because the bank explicitly classifies 20 as generics and 11 as incremental innovations. BNDES says the company already has more than 70 registered medicines and over 80 supplements; these are company-profile figures in the release.

The BNDES release defines radical innovation as work based on discovery of new molecules or compounds not previously available in the market. It notes the possibility of first patents from Althaia’s radical-development work and places the financing in a broader effort to support higher-risk projects with longer maturity periods and links between industry and research institutes. Those points explain why the first operation includes institutional partnership and research capacity alongside medicine candidates.

Data

Key figures

BNDES approves R$298 million for Althaia drug research and development

Amounts, counts and targets stated in the primary announcement.

Total approved financing
298 million BRL
2026-10-24 · Observed
Research and development financing
100 million BRL
2026-10-24 · Observed
Medicine development financing
198 million BRL
2026-10-24 · Observed
Medicines in development
31 count
2026-10-24 · Target
Generic products entering market for first time
20 count
2026-10-24 · Target
Incremental innovations
11 count
2026-10-24 · Target
Expected new R&D-center jobs
≥35 jobs
2026-10-24 · Estimate
Methodology

Transcribed from the named primary source; plans and estimates retain their stated basis. No derived figures are calculated.

Updated:

Structured coverage

Subjects and places

Subject proposals

Geographic references

Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.

  • Brazil · Place role: Coverage · Place type: Country or area · Location precision: Regional
    Evidence
Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Technology

RoslinCT wins grant of up to £7.25m for digital manufacturing in Scotland

Scottish Enterprise announced on 6 October that it had awarded cell-therapy manufacturer RoslinCT an R&D grant of up to £7.25 million for the digital transformation of its manufacturing operations in Scotland. The programme forms part of the company’s multi-year digital expansion plan.

RoslinCT (announcement published by Scottish Enterprise)1 min read Data included